IMPAX Laboratories, Inc. Launches Authorized Generic of Zomig (zolmitriptan) Tablets and Orally Disintegrating Tablets in the U.S.

Published: May 17, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

HAYWARD, Calif.--(BUSINESS WIRE)--Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that its generics division, Global Pharmaceuticals, commenced shipment of authorized generic ZomigĀ® (zolmitriptan) tablets and orally disintegrating tablets, 2.5 mg and 5 mg, in the U.S., as part of a Distribution, License, Development and Supply Agreement with AstraZeneca UK Limited (AstraZeneca).

Help employers find you! Check out all the jobs and post your resume.

Back to news